Developer docs
API playgroundTry for free, no card

Search company profiles

Ethypharm

Full company profile

uuid0009933

Namestring
Ethypharm
Legal namestring
ETHYPHARM SAS
Websiteurl
ethypharm.com
Company typeenum
Private
Founded yearint
1977
Descriptiontext

Ethypharm is a French specialty pharmaceutical company founded in 1977, headquartered in Saint-Cloud, France, that designs, develops, manufactures, and commercializes essential medicines focused on two therapeutic areas: Central Nervous System (CNS) disorders — particularly severe pain and opioid addiction — and Hospital Injectables for critical care. The company operates through a vertically integrated model spanning proprietary drug delivery platforms (Flashtab, Tmask, Nanosizing, Multicaps, Transmucosal, Locktab), six manufacturing sites across France, the UK, Spain, and China, and direct commercial affiliates in six key markets (France, Germany, UK, Italy, Spain, and China), complemented by distributor and licensee networks reaching 68+ countries. The product portfolio includes morphine-based pain treatments (NM-ESLON, NM-Ediat), the digital therapeutics deprexis and vorvida (via the Ethypharm Digital Therapy SAS unit), and recent additions such as Argatroban antithrombin agents, Penthrox, and Nefopam injectable.

The business generates revenue through three primary streams: direct pharmaceutical sales through the six affiliates (85% of pharma revenue), distribution and licensing in 68+ countries (15% of pharma revenue), and Contract Development and Manufacturing Organization (CDMO) services for other pharmaceutical companies (~19% of total revenue). Group net sales reached €435 million in 2024, with 39% derived from CNS and 31% from Hospital Injectables. Customers span hospitals, ICUs, emergency medicine departments, anesthesiologists, addiction treatment providers, healthcare NGOs (MSF, MEG, IDA Foundation), and pharmaceutical partners seeking CDMO services. Pricing is institutional B2B with no public list pricing.

Ethypharm is privately held with no public listing or disclosed institutional investor ownership. The company is led by President and CEO Denis Delval (appointed October 2022), with a management team including Chief Financial Officer Foucauld Ruyant, Chief Operating Officer Guilhem Maraval, Chief Commercial Operations Officer Xavier Lasserre, Chief Scientific Affairs Officer Cecile Paillous, and Chief Legal, Ethics & Compliance Officer Roseline Joannesse. The company employs approximately 1,800 staff globally, of which roughly 1,400 are in industrial operations. Recent strategic activity has been dominated by bolt-on M&A (Altan Pharma 2021, Argatroban business 2024), geographic expansion (Italy 2021), and portfolio diversification into digital therapeutics (2021) and medical cannabis (2021 onwards).

Short descriptiontext

Ethypharm is a French specialty pharmaceutical company founded in 1977 that develops, manufactures, and markets essential medicines for Central Nervous System disorders (severe pain and addiction) and Hospital Injectables, operating across 68+ countries through six direct affiliates and global distributor networks.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersSaint-cloud, France
HQ citystring
Saint-cloud
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices16 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, hospital injectables, pain management drugs, addiction treatment, drug delivery technology
Industry3 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharma Sales (Direct Affiliates)
TypeOne Time License
Description

85% of pharma revenue comes from direct sales through six affiliate companies in France, Germany, UK, Italy, Spain, and China. These affiliates sell Ethypharm's CNS and hospital injectable products directly to hospitals, pharmacies, healthcare professionals, and addiction treatment providers.

ethypharm.com
2Distribution
TypeTransaction Fee
Description

15% of pharma revenues come from distribution activities through a network of distributors across EMEA, North America, LATAM, and APAC.

ethypharm.com
3CDMO (Contract Development and Manufacturing)
TypeProfessional Services
Description

Contract Development and Manufacturing Organization activities contributing approximately 19% of revenue through partnerships with other pharmaceutical companies, providing flexible development and manufacturing solutions for small molecule APIs, advanced intermediates, oral solid dosage forms, and injectable products.

ethypharm.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1NM-ESLON
Description

Morphine sulfate extended release capsules for pain management

ethypharm.com
+8 more records
Core offering1 text field

Ethypharm designs, formulates, develops, manufactures, and markets specialty pharmaceutical products centered on Central Nervous System (CNS) disorders (severe pain and addiction treatment) and Hospital Injectables (critical care). It also operates as a Contract Development and Manufacturing Organization (CDMO), providing development and production services to third-party pharmaceutical clients, and has begun distributing digital therapies such as deprexis and vorvida alongside its CNS portfolio.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Operates in 68 countries worldwide
+3 more records
Product and service9 records
1NM-ESLON / NM-Ediat (morphine)
CategoryCNS / severe pain
Description

Specialty morphine formulations (including orodispersible and sustained-release presentations) for severe pain management, targeted at hospital and specialist pain clinics.

2Recivit (fentanyl)
CategoryCNS / severe pain
Description

Fentanyl-based specialty analgesic for severe pain, targeted at specialist prescribers and hospital settings under controlled-substance regulations.

3Argatroban portfolio (Argatra / Arganova / Novastan / Exembol)
CategoryHospital Injectables / critical care
Description

Argatroban injectable anticoagulant marketed under multiple brand names for use in critical care and interventional cardiology settings.

4Etiasa (Mesalazine)
CategorySpecialty pharmaceuticals
Description

Mesalazine specialty product for inflammatory bowel disease, distributed through Ethypharm's sales affiliates and licensee network.

5NOYADA (Captopril)
CategorySpecialty pharmaceuticals
Description

Captopril specialty cardiovascular product in Ethypharm's portfolio, distributed through its sales network.

6Nefopam HCl injectable
CategoryHospital Injectables / pain
Description

Nefopam hydrochloride injectable for moderate to severe pain in hospital and perioperative settings.

7Methadone / Buprenorphine / Naloxone addiction treatments
CategoryCNS / addiction treatment
Description

Specialty opioid-agonist and antagonist products used in opioid-dependence treatment programs, targeting addiction medicine specialists and treatment centers.

8Digital therapies (deprexis, vorvida)
CategoryDigital therapies / CNS
Description

Digital therapeutic programs (deprexis for depression, vorvida for alcohol use disorder) distributed alongside Ethypharm's CNS portfolio to support adherence and behavioral interventions in chronic CNS conditions.

9Contract Development and Manufacturing (CDMO) services
CategoryPharmaceutical services / CDMO
Description

Contract development and manufacturing services offered to other pharmaceutical companies, leveraging Ethypharm's specialty manufacturing capabilities and proprietary drug delivery platforms.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-13
Description

Licensing agreement with Medochemie for Ethypharm Iberia to commercialise Nefopam HCl 20mg/2ml injectable solution in Spain, an analgesic for moderate to severe pain.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-29
Description

Licensing agreement for marketing and distribution of Penthrox® (methoxyflurane), an inhaled analgesic for acute pain management, in France. Ethypharm responsible for marketing and distribution, with commercial activities expected to commence July 2025.

3Mitsubishi Tanabe Pharma Corporation (MTPC)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-06-17
Description

Agreement to acquire the selective antithrombin agent Argatroban monohydrate (branded as Argatra®, Arganova®, Novastan®, Exembol®) in Europe from MTPC.

ethypharm.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Partnership with French start-up Helioclim to install a reversible solar water/ammonia absorption machine incorporating internal energy storage powered by thermal solar collectors, targeting 15% reduction in electricity and gas consumption per year from 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-21
Description

Ethypharm acquired Altan Pharma for approximately €100 million, marking entry into Spain as a fifth European country. Malin, which owned about 65% of Altan, received approximately €68 million in net proceeds. Transaction closed in H2 2021, pending regulatory approval. Altan was led by Manuel Casegas as General Manager.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-06
Description

Ethypharm acquired exclusive rights for two CE-marked digital therapies: deprexis® (for depression) and vorvida® (for addiction), developed by GAIA AG. A new business unit, Ethypharm Digital Therapy SAS, was established in May 2021 to lead this initiative, with Hélène Moore appointed as Head of Digital Therapy.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-03-17
Description

Exclusive licence agreement for sale of medical cannabis extracts in Germany, the most important European market for medical cannabis. Ethypharm positions this as a step toward becoming a leading provider of medical cannabis products in Europe.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-26
Description

Collaboration to bring medical cannabis produced under EU GMP standards to patients in France. Aurora supplies products; Ethypharm's French subsidiary (Laboratoires Ethypharm) handles pharmaceutical distribution. One of six producer-distributor tandems selected by ANSM for the French medical cannabis pilot programme. Extended in 2023.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-19
Description

Exclusive licensing agreement for the development, registration, and marketing of Kigabeq® (vigabatrin) for the first-line treatment of infantile spasms (West syndrome) in the People's Republic of China.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Active Group strategic partnership with the NGO Douleurs Sans Frontières (Pain Without Borders) to support pain management access in underserved regions.

11Laboratoires CTRS
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-11-10
Description

Exclusive partnership agreement for registration and commercialisation of Orphacol® (orphan medicine for rare inborn errors in primary bile acid synthesis) in the People's Republic of China.

ethypharm.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-07-04
Description

Agreement granting Ethypharm exclusive distribution rights in Germany for four injectable pain-management solutions in the CNS field.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CDMO with capabilities in sterile injectables, oral solid dose, and complex formulations. Directly comparable to Ethypharm's CDMO segment (~19% of revenue), though significantly larger in scale and scope.

2Recipharm
TypeEmerging player
Description

European CDMO offering contract development and manufacturing for oral solid dose and sterile products. Comparable CDMO service portfolio to Ethypharm, particularly around small-molecule oral solids and injectables.

TypeBroad incumbent
Description

US-listed specialty pharmaceutical company with hospital injectables and CNS franchises. Comparable to Ethypharm across both Hospital Injectables and CNS pain/addiction, though materially larger and more US-centric.

TypeDirect peer
Description

German privately held specialty pharmaceutical company focused on pain management, including opioids and innovative non-opioid treatments. Direct competitor to Ethypharm in CNS/pain, especially across European markets.

TypeDirect peer
Description

Specialty pharmaceutical company focused on opioid addiction treatment (buprenorphine-based Suboxone/Sublocade) and CNS. Highly comparable to Ethypharm's addiction-treatment franchise and leadership position in the UK.

6Endo International
TypeBroad incumbent
Description

US specialty pharmaceutical company with a strong pain management (including opioids) and sterile injectables franchise. Comparable to Ethypharm in CNS pain and sterile injectables, though more US-focused and currently operating under restructuring.

TypeBroad incumbent
Description

European specialty generics and consumer healthcare company with broad portfolio across CNS and hospital products. Comparable to Ethypharm as a privately held European specialty generics platform with M&A-driven growth.

TypeDirect peer
Description

Public specialty pharma with leading injectable generics and CNS franchises across MENA, Europe, and the US. Directly comparable manufacturing scale and CDMO-style injectable capabilities to Ethypharm's Hospital Injectables business.

TypeEmerging player
Description

Swedish specialty pharma with proprietary drug-delivery technology (FluidCrystal) focused on CNS, opioid dependence, and pain. Comparable to Ethypharm in CNS specialization and technology-driven formulation differentiation.

TypeBroad incumbent
Description

European specialty pharmaceutical company focused on dermatology and CNS, with commercial presence across the same five large European markets as Ethypharm. Comparable mid-size European specialty pharma peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ethypharm

Specialty Pharmaceuticalsethypharm.com

Ethypharm is a French specialty pharmaceutical company founded in 1977 that develops, manufactures, and markets essential medicines for Central Nervous System disorders (severe pain and addiction) and Hospital Injectables, operating across 68+ countries through six direct affiliates and global distributor networks.

What Ethypharm does

Ethypharm is a French specialty pharmaceutical company founded in 1977, headquartered in Saint-Cloud, France, that designs, develops, manufactures, and commercializes essential medicines focused on two therapeutic areas: Central Nervous System (CNS) disorders — particularly severe pain and opioid addiction — and Hospital Injectables for critical care. The company operates through a vertically integrated model spanning proprietary drug delivery platforms (Flashtab, Tmask, Nanosizing, Multicaps, Transmucosal, Locktab), six manufacturing sites across France, the UK, Spain, and China, and direct commercial affiliates in six key markets (France, Germany, UK, Italy, Spain, and China), complemented by distributor and licensee networks reaching 68+ countries. The product portfolio includes morphine-based pain treatments (NM-ESLON, NM-Ediat), the digital therapeutics deprexis and vorvida (via the Ethypharm Digital Therapy SAS unit), and recent additions such as Argatroban antithrombin agents, Penthrox, and Nefopam injectable.

The business generates revenue through three primary streams: direct pharmaceutical sales through the six affiliates (85% of pharma revenue), distribution and licensing in 68+ countries (15% of pharma revenue), and Contract Development and Manufacturing Organization (CDMO) services for other pharmaceutical companies (~19% of total revenue). Group net sales reached €435 million in 2024, with 39% derived from CNS and 31% from Hospital Injectables. Customers span hospitals, ICUs, emergency medicine departments, anesthesiologists, addiction treatment providers, healthcare NGOs (MSF, MEG, IDA Foundation), and pharmaceutical partners seeking CDMO services. Pricing is institutional B2B with no public list pricing.

Ethypharm is privately held with no public listing or disclosed institutional investor ownership. The company is led by President and CEO Denis Delval (appointed October 2022), with a management team including Chief Financial Officer Foucauld Ruyant, Chief Operating Officer Guilhem Maraval, Chief Commercial Operations Officer Xavier Lasserre, Chief Scientific Affairs Officer Cecile Paillous, and Chief Legal, Ethics & Compliance Officer Roseline Joannesse. The company employs approximately 1,800 staff globally, of which roughly 1,400 are in industrial operations. Recent strategic activity has been dominated by bolt-on M&A (Altan Pharma 2021, Argatroban business 2024), geographic expansion (Italy 2021), and portfolio diversification into digital therapeutics (2021) and medical cannabis (2021 onwards).

Ethypharm firmographics

Firmographics
Name
Ethypharm
Legal name
ETHYPHARM SAS
Website
https://ethypharm.com
Company type
Private
Founded year
1977
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Ethypharm is a French specialty pharmaceutical company founded in 1977 that develops, manufactures, and markets essential medicines for Central Nervous System disorders (severe pain and addiction) and Hospital Injectables, operating across 68+ countries through six direct affiliates and global distributor networks.
Ownership category
akta.pro rank

Ethypharm industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Specialty pharmaceuticals
  • Hospital injectables
  • Pain management drugs
  • Addiction treatment
  • Drug delivery technology

Where Ethypharm is headquartered

Location

Headquarters

HQ city
Saint-cloud
HQ country
France
HQ region
Europe

Offices16 records

Markets served

Ethypharm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. Pharma Sales (Direct Affiliates): 85% of pharma revenue comes from direct sales through six affiliate companies in France, Germany, UK, Italy, Spain, and China. These affiliates sell Ethypharm's CNS and hospital injectable products directly to hospitals, pharmacies, healthcare professionals, and addiction treatment providers.
  2. Distribution: 15% of pharma revenues come from distribution activities through a network of distributors across EMEA, North America, LATAM, and APAC.
  3. CDMO (Contract Development and Manufacturing): Contract Development and Manufacturing Organization activities contributing approximately 19% of revenue through partnerships with other pharmaceutical companies, providing flexible development and manufacturing solutions for small molecule APIs, advanced intermediates, oral solid dosage forms, and injectable products.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Ethypharm product offering

Product offering

Core offering

Ethypharm designs, formulates, develops, manufactures, and markets specialty pharmaceutical products centered on Central Nervous System (CNS) disorders (severe pain and addiction treatment) and Hospital Injectables (critical care). It also operates as a Contract Development and Manufacturing Organization (CDMO), providing development and production services to third-party pharmaceutical clients, and has begun distributing digital therapies such as deprexis and vorvida alongside its CNS portfolio.

Differentiator

Problem solved

Functional benefit

Brands

  • NM-ESLON: Morphine sulfate extended release capsules for pain management
  • NM-Ediat
  • NOYADA
  • Etiasa
  • Recivit
  • Argatra
  • Arganova
  • Novastan
  • Exembol

Products and services

  • NM-ESLON / NM-Ediat (morphine) Specialty morphine formulations (including orodispersible and sustained-release presentations) for severe pain management, targeted at hospital and specialist pain clinics.
  • Recivit (fentanyl) Fentanyl-based specialty analgesic for severe pain, targeted at specialist prescribers and hospital settings under controlled-substance regulations.
  • Argatroban portfolio (Argatra / Arganova / Novastan / Exembol) Argatroban injectable anticoagulant marketed under multiple brand names for use in critical care and interventional cardiology settings.
  • Etiasa (Mesalazine) Mesalazine specialty product for inflammatory bowel disease, distributed through Ethypharm's sales affiliates and licensee network.
  • NOYADA (Captopril) Captopril specialty cardiovascular product in Ethypharm's portfolio, distributed through its sales network.
  • Nefopam HCl injectable Nefopam hydrochloride injectable for moderate to severe pain in hospital and perioperative settings.
  • Methadone / Buprenorphine / Naloxone addiction treatments Specialty opioid-agonist and antagonist products used in opioid-dependence treatment programs, targeting addiction medicine specialists and treatment centers.
  • Digital therapies (deprexis, vorvida) Digital therapeutic programs (deprexis for depression, vorvida for alcohol use disorder) distributed alongside Ethypharm's CNS portfolio to support adherence and behavioral interventions in chronic CNS conditions.
  • Contract Development and Manufacturing (CDMO) services Contract development and manufacturing services offered to other pharmaceutical companies, leveraging Ethypharm's specialty manufacturing capabilities and proprietary drug delivery platforms.

Quantifiable outcome

  • Operates in 68 countries worldwide
  • +3 more outcomes

Companies that use Ethypharm

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Ethypharm technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Ethypharm partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered minor and core.

  • MedochemieminorChannel Partner/ Reseller/ Distributor · 13 May 2025Licensing agreement with Medochemie for Ethypharm Iberia to commercialise Nefopam HCl 20mg/2ml injectable solution in Spain, an analgesic for moderate to severe pain.
  • Medical Developments International (MDI)coreChannel Partner/ Reseller/ Distributor · 29 April 2025Licensing agreement for marketing and distribution of Penthrox® (methoxyflurane), an inhaled analgesic for acute pain management, in France. Ethypharm responsible for marketing and distribution, with commercial activities expected to commence July 2025.
  • Mitsubishi Tanabe Pharma Corporation (MTPC)coreTechnology or Integration · 17 June 2024Agreement to acquire the selective antithrombin agent Argatroban monohydrate (branded as Argatra®, Arganova®, Novastan®, Exembol®) in Europe from MTPC.
  • HelioclimminorStrategic or Co-development Partner · 1 January 2024Partnership with French start-up Helioclim to install a reversible solar water/ammonia absorption machine incorporating internal energy storage powered by thermal solar collectors, targeting 15% reduction in electricity and gas consumption per year from 2025.
  • Altan Pharma (Acquisition)coreStrategic or Co-development Partner · 21 June 2021Ethypharm acquired Altan Pharma for approximately €100 million, marking entry into Spain as a fifth European country. Malin, which owned about 65% of Altan, received approximately €68 million in net proceeds. Transaction closed in H2 2021, pending regulatory approval. Altan was led by Manuel Casegas as General Manager.
  • GAIA AGcoreStrategic or Co-development Partner · 6 April 2021Ethypharm acquired exclusive rights for two CE-marked digital therapies: deprexis® (for depression) and vorvida® (for addiction), developed by GAIA AG. A new business unit, Ethypharm Digital Therapy SAS, was established in May 2021 to lead this initiative, with Hélène Moore appointed as Head of Digital Therapy.
  • Clever LeavescoreTechnology or Integration · 17 March 2021Exclusive licence agreement for sale of medical cannabis extracts in Germany, the most important European market for medical cannabis. Ethypharm positions this as a step toward becoming a leading provider of medical cannabis products in Europe.
  • Aurora EuropecoreStrategic or Co-development Partner · 26 January 2021Collaboration to bring medical cannabis produced under EU GMP standards to patients in France. Aurora supplies products; Ethypharm's French subsidiary (Laboratoires Ethypharm) handles pharmaceutical distribution. One of six producer-distributor tandems selected by ANSM for the French medical cannabis pilot programme. Extended in 2023.
  • ORPHELIA PharmacoreStrategic or Co-development Partner · 19 January 2021Exclusive licensing agreement for the development, registration, and marketing of Kigabeq® (vigabatrin) for the first-line treatment of infantile spasms (West syndrome) in the People's Republic of China.
  • Douleurs Sans FrontièrescoreStrategic or Co-development Partner · 1 January 2021Active Group strategic partnership with the NGO Douleurs Sans Frontières (Pain Without Borders) to support pain management access in underserved regions.
  • Laboratoires CTRScoreStrategic or Co-development Partner · 10 November 2020Exclusive partnership agreement for registration and commercialisation of Orphacol® (orphan medicine for rare inborn errors in primary bile acid synthesis) in the People's Republic of China.
  • KalceksminorChannel Partner/ Reseller/ Distributor · 4 July 2019Agreement granting Ethypharm exclusive distribution rights in Germany for four injectable pain-management solutions in the CNS field.

Scale indicators7 records

Recent moves8 records

Expansion highlights7 records

Ethypharm competitors and assessment

Company assessment

Broad incumbents

  • Catalent: Global CDMO with capabilities in sterile injectables, oral solid dose, and complex formulations. Directly comparable to Ethypharm's CDMO segment (~19% of revenue), though significantly larger in scale and scope.
  • Mallinckrodt Pharmaceuticals: US-listed specialty pharmaceutical company with hospital injectables and CNS franchises. Comparable to Ethypharm across both Hospital Injectables and CNS pain/addiction, though materially larger and more US-centric.
  • Endo International: US specialty pharmaceutical company with a strong pain management (including opioids) and sterile injectables franchise. Comparable to Ethypharm in CNS pain and sterile injectables, though more US-focused and currently operating under restructuring.
  • Stada Arzneimittel: European specialty generics and consumer healthcare company with broad portfolio across CNS and hospital products. Comparable to Ethypharm as a privately held European specialty generics platform with M&A-driven growth.
  • Almirall: European specialty pharmaceutical company focused on dermatology and CNS, with commercial presence across the same five large European markets as Ethypharm. Comparable mid-size European specialty pharma peer.

Emerging players

  • Recipharm: European CDMO offering contract development and manufacturing for oral solid dose and sterile products. Comparable CDMO service portfolio to Ethypharm, particularly around small-molecule oral solids and injectables.
  • Camurus: Swedish specialty pharma with proprietary drug-delivery technology (FluidCrystal) focused on CNS, opioid dependence, and pain. Comparable to Ethypharm in CNS specialization and technology-driven formulation differentiation.

Direct peers

  • Grünenthal: German privately held specialty pharmaceutical company focused on pain management, including opioids and innovative non-opioid treatments. Direct competitor to Ethypharm in CNS/pain, especially across European markets.
  • Indivior: Specialty pharmaceutical company focused on opioid addiction treatment (buprenorphine-based Suboxone/Sublocade) and CNS. Highly comparable to Ethypharm's addiction-treatment franchise and leadership position in the UK.
  • Hikma Pharmaceuticals: Public specialty pharma with leading injectable generics and CNS franchises across MENA, Europe, and the US. Directly comparable manufacturing scale and CDMO-style injectable capabilities to Ethypharm's Hospital Injectables business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Ethypharm social profiles

Digital presence

Ethypharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ethypharm leadership team

Management profile

Number of profiles

Profiles3 records

Ethypharm subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

Ethypharm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ethypharm M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ethypharm

What does Ethypharm do?

Ethypharm designs, formulates, develops, manufactures, and markets specialty pharmaceutical products centered on Central Nervous System (CNS) disorders (severe pain and addiction treatment) and Hospital Injectables (critical care). It also operates as a Contract Development and Manufacturing Organization (CDMO), providing development and production services to third-party pharmaceutical clients, and has begun distributing digital therapies such as deprexis and vorvida alongside its CNS portfolio.

Is Ethypharm a public or private company?

Ethypharm is a private company. It is classified as unknown and is currently operating.

When was Ethypharm founded?

Ethypharm was founded in 1977. It employs 1,001 to 5,000 people.

Where is Ethypharm based?

Ethypharm is headquartered in Saint-cloud, France, in the Europe region.

How does Ethypharm make money?

Three revenue lines are on record. Pharma Sales (Direct Affiliates) is the primary driver. The others are distribution and CDMO (Contract Development and Manufacturing).

Who are Ethypharm's main competitors?

Broad incumbents on record are Catalent, Mallinckrodt Pharmaceuticals, Endo International, Stada Arzneimittel and Almirall. Emerging players are Recipharm and Camurus. Direct peers are Grünenthal, Indivior and Hikma Pharmaceuticals.

Does Ethypharm have an API?

No public API is recorded for Ethypharm.

What industry is Ethypharm in?

Ethypharm's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pharmaphorumFuture Health report: Expert opinion on digital therapeuticsHealthware Group released an expert opinion report proposing the integration of digital therapeutics into depression care pathways within the Italian national health service to address unmet treatment needs. The document highlights the clinical efficacy of specific interventions like deprexis and calls for defined regulatory and reimbursement criteria to enhance accessibility and reduce waiting times. This initiative, supported by Ethypharm Digital Therapy, aims to modernize mental health care in Italy amid rising prevalence rates and current service gaps.PR NewswireEthypharm expands its Mesalazine (Etiasa®) Portfolio in ChinaEthypharm's Chinese affiliate acquired a Mesalazine suppository from Jiangsu Anbison Pharmaceutical. The acquisition expands Ethypharm's Mesalazine portfolio, with Etiasa® holding about 30% market share in China. The move aims to meet patient demand and extend Etiasa's life cycle.PR NewswireEthypharm gibt die Ernennung von Xavier LASSERRE zum neuen Chief Commercial Officer bekanntEthypharm has appointed Xavier LASSERRE as its new Chief Commercial Officer, effective June 12, 2023. LASSERRE brings over 25 years of pharmaceutical industry experience, having previously served as Head of Commercial Operations at Zentiva Group, and will oversee Ethypharm's operations across the UK, China, France, Spain, Germany, and Italy. He will join Ethypharm's Executive Committee and lead commercial strategy, market expansion, and business development initiatives.PR NewswireEthypharm annonce la nomination de Xavier LASSERRE en tant que nouveau Directeur CommercialEthypharm announced the appointment of Xavier Lasserre as Chief Commercial Officer, effective June 12, 2023, replacing the previous commercial leadership role. Lasserre brings over 25 years of pharmaceutical industry experience, having previously served as Chief Commercial Operations Officer at Zentiva, a European pharmaceutical company. He will join Ethypharm's executive committee and oversee commercial operations across the company's subsidiaries in the UK, China, France, Spain, Germany, and Italy, as well as distribution and licensing activities.PR NewswireAurora et Ethypharm réaffirment leur engagement à promouvoir l'accès au cannabis médical pour les patients françaisAurora Europe GmbH and Ethypharm have been re-selected by France's Direction Générale de la Santé as exclusive suppliers of dried medical cannabis flowers for the French pilot program, which has been extended until March 2024. The two companies signed their original agreement to serve the French pilot program in October 2020, with Aurora providing EU GMP-manufactured cannabis and logistics while Ethypharm handles distribution and pharmacovigilance through its French subsidiary.PR NewswireAurora and Ethypharm Reaffirm their Commitment to Promote Access to Medical Cannabis for French PatientsAurora Europe GmbH, a subsidiary of Aurora Cannabis Inc., and Ethypharm have been re-selected by the French General Directorate of Health as exclusive suppliers of dried medical cannabis flower for France's medical cannabis pilot program, which has been extended until March 2024. The partnership, originally signed in October 2020 under ANSM oversight, has Aurora supplying medical cannabis and EU GMP manufacturing and logistics, while Ethypharm handles distribution and pharmacovigilance. The companies reaffirmed their commitment to improving access to medical cannabis in Europe through this ongoing collaboration with French health authorities.PR NewswireAurora and Ethypharm Reaffirm their Commitment to Promote Access to Medical Cannabis for French PatientsAurora Europe GmbH and Ethypharm have been selected by the French General Directorate of Health to remain the exclusive suppliers of dried medical cannabis flower for the national pilot program until March 2024. This re-selection follows a tender process initiated in January 2023, confirming their partnership to provide EU GMP-compliant products and logistics support under the supervision of the ANSM.PR NewswireDenis DELVAL zum CEO der Ethypharm Group ernanntThe supervisory board of Ethypharm Group has appointed Denis Delval as its new CEO. Delval brings extensive experience from previous leadership roles at major pharmaceutical companies including Bayer, Fournier Pharma, ALK, and LFB. He will lead the European company, which specializes in central nervous system treatments and injectable hospital medications.PR NewswireDenis DELVAL is appointed President of the Ethypharm GroupThe Supervisory Board of Ethypharm Group has appointed Denis Delval as its new CEO, effective October 10, 2022. Delval brings extensive pharmaceutical industry experience from previous leadership roles at Bayer, ALK, and LFB. He stated his intention to continue the group's development in Central Nervous System diseases and hospital injectables.PR NewswireDenis DELVAL est nommé Président du Groupe EthypharmThe Supervisory Board of Groupe Ethypharm has appointed Denis Delval as its new CEO, effective immediately. Delval brings extensive experience from major pharmaceutical groups such as Bayer, ALK, and LFB to lead the European specialty pharma company. He stated his intention to mobilize energy and continue the group's development in central nervous system and hospital injectable treatments.